Biocon Biologics Recognized as Asia IP Elite for 2025 by IAM

Biocon Biologics Limited, a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON), announced today that it has been recognized as an Asia IP Elite for 2025 by IAM (Intellectual Asset Management), the world's leading Intellectual Property (IP) publication.

This prestigious accolade is awarded to a select group of Asia-based organizations that have demonstrated exceptional IP value creation and are considered leaders in the region. The award was presented during IPBC Asia, held in Tokyo from November 18-20, 2025.

Biocon first earned its place on the Asia IP Elite list in 2016, becoming the first and only Indian pharmaceutical company to be featured for its robust IP management and consistent IP value creation. In subsequent years, Biocon Biologics has continued this legacy, with the two entities together being among the few Indian pharmaceutical companies consistently featured on the Asia IP Elite roster. The 2025 recognition marks the ninth consecutive year that Biocon and Biocon Biologics have appeared on this prestigious list.

Shreehas Tambe, CEO & Managing Director, Biocon Biologics, said: "Our inclusion in the Asia IP Elite list for 2025 marks the ninth consecutive year that Biocon and Biocon Biologics have appeared on this prestigious list. This reflects our sustained commitment to innovation and strong intellectual property strategy. It reinforces our growing stature as a global biosimilars leader and the role of our IP strategy in expanding access to high-quality, affordable therapies for patients worldwide."

Each year, the IAM editorial team conducts an extensive research process, incorporating both quantitative and qualitative analyses, to highlight an exclusive group of leading corporations and research institutions as inductees into the Asia IP Elite.

Shares of Biocon Limited was last trading in BSE at Rs. 384.65 as compared to the previous close of Rs. 390.55. The total number of shares traded during the day was 31170 in over 1084 trades.

The stock hit an intraday high of Rs. 391.95 and intraday low of 384.20. The net turnover during the day was Rs. 12044725.00.

Source : Equity Bulls

Keywords

Biocon INE376G01013 Biotechnology BioconBiologics